Drug · CHEMBL629
AMITRIPTYLINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. AMITRIPTYLINE. Drugs and targets, record CHEMBL629. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL629
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | Norepinephrine transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6530 |
| SLC6A4 | Sodium-dependent serotonin transporter | Serotonin transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6532 |
Source ChEMBL
Diseases32
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 32Source Open Targets
See all 32 diseasesTrials103
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01581281 | The Childhood and Adolescent Migraine Prevention Study | Phase 3 | 488 | 2017-08-10 | amitriptyline | Its name | ClinicalTrials.gov |
| NCT00471445 | Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients | Phase 3 | 462 | 2015-06-10 | amitriptyline | Its name | ClinicalTrials.gov |
| NCT00475904 | A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN) | Phase 2 | 360 | 2011-07-06 | amitriptyline | Its name | ClinicalTrials.gov |
| NCT00248651 | Functional Dyspepsia Treatment Trial | Phase 2/3 | 292 | 2014-07-25 | amitriptyline | Its name | ClinicalTrials.gov |
| NCT00124306 | Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS) | Phase 3 | 271 | 2025-10-07 | amitriptyline | Its name | ClinicalTrials.gov |
| NCT00476151 | A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy | Phase 2 | 226 | 2011-05-17 | amitriptyline | Its name | ClinicalTrials.gov |
| NCT01856270 | Amitriptyline to Prevent Headache After Traumatic Brain Injury | Phase 2 | 50 | 2017-12-22 | amitriptyline | Its name | ClinicalTrials.gov |
| NCT02434523 | Trial of the Treatment of Chronic Laryngitis With Amitryptiline | Phase 2/3 | 30 | 2016-11-30 | amitriptyline | Its name | ClinicalTrials.gov |
| NCT01206478 | Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age | Phase 2 | 21 | 2016-08-15 | amitriptyline | Its name | ClinicalTrials.gov |
| NCT03096444 | Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine | Phase 2 | 13 | 2019-07-02 | amitriptyline | Its name | ClinicalTrials.gov |
1 to 10 of 103
See all 103 trialsComparisons in its trials19
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Amitriptyline and Ketamine Hydrochloride Topical Analgesic cr vs Placebo Cream: serious adverse events | 4 of 227 | 4 of 231 | 458 | NCT00471445 | Trial comparisons |
| 1 - Amitriptyline vs 2 - Placebo: deaths from any cause | 0 of 135 | 0 of 136 | 271 | NCT00124306 | Trial comparisons |
| 1 - Amitriptyline vs 2 - Placebo: serious adverse events | 2 of 135 | 3 of 136 | 271 | NCT00124306 | Trial comparisons |
| Amitriptyline 4% Ketamine 2% Cream vs Placebo Cream: serious adverse events | 0 of 114 | 0 of 112 | 226 | NCT00476151 | Trial comparisons |
| Amitriptyline Immediate vs Amitriptyline Delayed: deaths from any cause | 0 of 24 | 0 of 26 | 50 | NCT01856270 | Trial comparisons |
| Amitriptyline Immediate vs Amitriptyline Delayed: serious adverse events | 0 of 24 | 0 of 26 | 50 | NCT01856270 | Trial comparisons |
| Amitriptyline vs Placebo: Lost to Follow up | 5 of 15 | 6 of 15 | 30 | NCT02434523 | Trial comparisons |
| Amitriptyline vs Placebo: serious adverse events | 0 of 15 | 0 of 15 | 30 | NCT02434523 | Trial comparisons |
| Amitriptyline, Megestrol vs Placebo, Megestrol: serious adverse events | 0 of 9 | 0 of 12 | 21 | NCT01206478 | Trial comparisons |
| Medications vs Placebo: serious adverse events | 0 of 9 | 0 of 9 | 18 | NCT02099006 | Trial comparisons |
1 to 10 of 19
See all 19 comparisons in its trialsPapers from its trials77
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials5
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Symbol Coding | 1 | 0 | ConductCognition |
| Task Switching Test | 1 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
| Trail Making Test B | 1 | 0 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL629
GET https://conductscience.org/api/drugs/v1/CHEMBL629/diseases?page=2